MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c
Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines.
Moderna and partner Merck & Co have fleshed out the data from their clinical trial of personalised mRNA vaccine for melanoma, saying the results support the start of a
A regimen of Roche's Tecentriq and Avastin has become the first immunotherapy-based combination to reduce the risk of liver cancer returning after surgery to remove the tumour in a phase 3
Bristol-Myers Squibb's Opdivo has shown efficacy when used as a post-surgery (adjuvant) treatment for patients with melanoma, extending the time before the disease recurrence or patient dea
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.